This article is rated C-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | |||||||||||
|
Bcr-Abl tyrosine-kinase inhibitor received a peer review by Wikipedia editors, which is now archived. It may contain ideas you can use to improve this article. |
Page created as Discovery and development of Bcr-Abl tyrosine kinase inhibitors
Hinemash6 ( talk) 00:17, 16 November 2010 (UTC)
In the development of ponatinib section, the second stage molecule is described as 'AP24163', yet the second molecule shown in the schematic diagram is 'AP23146' (i.e. very similar). Are these they same molecule, in fact, and is either the label or the description wrong? (92.24.125.151 UTC 15:04 November 21, 2010)
Could intro say if there is no use for Bcr-Abl tyrosine kinase inhibitors other than to treat CML ? Perhaps the article should be renamed 'Bcr-Abl tyrosine kinase inhibitors for CML' ? Rod57 ( talk) 12:23, 23 November 2010 (UTC)
There is a mistake in the chemical structure of bosutinib. It contain methoxyphenyl moiety not phenoxy. It is now corrected. —Preceding unsigned comment added by 193.167.226.153 ( talk) 10:45, 24 November 2010 (UTC)
This article is rated C-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | |||||||||||
|
Bcr-Abl tyrosine-kinase inhibitor received a peer review by Wikipedia editors, which is now archived. It may contain ideas you can use to improve this article. |
Page created as Discovery and development of Bcr-Abl tyrosine kinase inhibitors
Hinemash6 ( talk) 00:17, 16 November 2010 (UTC)
In the development of ponatinib section, the second stage molecule is described as 'AP24163', yet the second molecule shown in the schematic diagram is 'AP23146' (i.e. very similar). Are these they same molecule, in fact, and is either the label or the description wrong? (92.24.125.151 UTC 15:04 November 21, 2010)
Could intro say if there is no use for Bcr-Abl tyrosine kinase inhibitors other than to treat CML ? Perhaps the article should be renamed 'Bcr-Abl tyrosine kinase inhibitors for CML' ? Rod57 ( talk) 12:23, 23 November 2010 (UTC)
There is a mistake in the chemical structure of bosutinib. It contain methoxyphenyl moiety not phenoxy. It is now corrected. —Preceding unsigned comment added by 193.167.226.153 ( talk) 10:45, 24 November 2010 (UTC)